首页 诺和诺德(usNVO)-基本信息

诺和诺德(usNVO)-基本信息

日报更新时间:07-02 06:53

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:诺和诺德


英文名称:Novo-Nordisk A/S


行业:医疗


简介:Novo Nordisk A/S于1989年成立,由两家丹麦公司,诺德根措夫特A/S和Novo工业A/S的合并而成


电话:45-44448888


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 持股信息
  • 领导人信息

诺和诺德是世界领先的生物制药公司,在糖尿病领域、生长激素领域、血友病领域提供制品和服务。Novo Nordisk A/S是一家医疗保健开发和销售商,拥有一系列可治疗糖尿病的药品组合。Novo Nordisk公司产品胰岛素和其他药物产品在179个国家销售,包括美国、日本、巴西、俄国、印度、中国和其它欧洲国家市场。诺和诺德公司主要产品:人胰岛素系列-诺和灵 诺和针 诺和英 以及注射胰岛素产品诺和笔三和诺和笔四(可回调注射量)、儿童专用胰岛素注射笔(可注射0.5个单位)、还有最新的诺和笔5(带液晶屏数字显示)等;新一代速效胰岛素注射液 诺和锐;促胰岛素分泌剂 诺和龙;人胰高血糖素 诺和生诺和诺德Novo Nordisk(NVO)历史沿革: 1923 诺德胰岛素实验室(Nordisk Insulinlaboratorium)成立 1925 诺和治疗实验室(Novo Terapeutisk Laboratorium)成立 1932 诺德胰岛素实验室成立Steno纪念医院 1938 诺和公司成立Hvidøre糖尿病疗养院 1941 诺和公司推出其第一个酶产品 - 胰蛋白酶,它提取自动物胰腺,被用于制革前的皮革软化 1946 诺德公司开发出中效胰岛素 1947 诺和公司推出第一个通过发酵制造出的产品 - 诺和青霉素 1953 诺和公司推出长效胰岛素锌悬浮液 - Lente® 1963 诺和公司通过发酵技术生产的第一个洗涤剂酶Alcalase®问世 1973 诺德公司推出用于治疗生长激素缺乏症的生长激素 Nanormon®。该生长激素是从人脑垂体中提取出来的 1973 推出最纯的单组份胰岛素 1974 诺和公司B股在哥本哈根证券交易所挂牌交易 1977 推出供绝经期妇女使用的合成口服激素代替治疗产品 - Trisequens® 1981 诺和公司成为在纽约证券交易所挂牌交易的第一家北欧公司 1982 推出世界上第一个等同于人胰岛素的人单组份胰岛素,它提取自猪胰岛并经转变成为人胰岛素 1984 推出供绝经后妇女使用的合成口服激素代替治疗产品 - Kliogest® 1985 推出诺和笔® -- 笔式胰岛素注射给药器,胰岛素笔芯可替换 1987 诺和公司开始利用基因工程酵母细胞生产人胰岛素 1988 诺德公司推出基因工程生产的人生长激素 - Norditropin® 1989 诺和工业公司和诺德根措夫特公司合并,诺和诺德公司成立 1989 推出世界上第一个预充型胰岛素注射器 - NovoLet® 1992 Steno纪念医院和Hvidøre医院合并,Steno糖尿病中心建立 1992 推出抑郁症治疗药物 - Seroxat® 1994 年诺和诺德公司是丹麦第一家发布环境报告的企业,也是世界上最早出版环境报告的企业之一 1996 面向血友病患者的血液注射液——诺其® NovoSeven® 开始销售 1998 在美国和许多欧洲国家推出NovoNorm®/Prandin® - 一种治疗2型糖尿病的新型口服药 1998 Activelle® -- 第一种供绝经后妇女使用的低剂量持续服用的合成口服激素代替治疗药物 1999 世界第一个使用専用注射器系统的液体生长激素Norditropin SimpleXx®S注销售 1999 世界上第一个具有内置记忆功能的电子胰岛素注射器 - 诺和英®在欧洲上市 1999 推出第一个速效胰岛素类似物 - 诺和锐® (在美国的注册商标为NovoLog®) 2000 在德国推出Novofem™ - 一种低剂量序贯治疗的合成的口服激素代替治疗药物,两年后该产品也在其它国家上市 2000 诺和诺德公司分成隶属诺和集团的三个独立运营公司:诺和诺德公司、诺维信公司及诺和公司 2001 推出InnoLet® - 第一个专为视力较弱和手脚不便的糖尿病患者设计的胰岛素给药系统上市 2001 推出世界上第一个集血糖测试和胰岛素注射系统功能于一身的产品 - InDuo® 2001 推出NovoRapid®FlexPen®及Insulatard®(NPH) FlexPen®。FlexPen®是一种便于使用的新型预充型胰岛素笔 2001 诺和诺德公司收购巴西制药公司Biobras 2001 世界糖尿病基金会设立 2002 二相性人工合成胰岛素类似物诺和混合NovoMix®30开始销售 2004 持效型胰岛素类似物 Levemir®推向市场 2004 诺和灵®特充®上市 2005 诺和锐®30上市 2009 第一个每日使用的人类GLP-1类似物Victoza®销售,针对二型糖尿病患者

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Parametric Portfolio Associates LLC 2005391 0.08% 42519 2.17% 2019-03-31
Fayez Sarofim & Company 4471252 0.19% 10942 0.25% 2019-03-31
State Street Corporation 4586096 0.19% -155940 -3.29% 2019-03-31
Folketrygdfondet 5252591 0.22% -480000 -8.37% 2019-03-31
Arrowstreet Capital Limited Partnership 6308565 0.27% -272798 -4.15% 2019-03-31
BlackRock Inc 8443407 0.36% 7159 0.08% 2019-03-31
Bank of America Corporation 12536293 0.53% 843124 7.21% 2019-03-31
Fisher Asset Management, LLC 14579672 0.61% 376737 2.65% 2019-03-31
Loomis Sayles & Company LP 20886188 0.88% 146494 0.71% 2019-03-31
State Farm Mutual Automobile Ins Co 4209698 0.18% -409316 -8.86% 2019-03-31
Sustainable Growth Advisers, LP 3538202 0.15% -74043 -2.05% 2019-03-31
Ameriprise Financial Inc 2079414 0.09% -167069 -7.44% 2019-03-31
Boston Partners Global Investors, Inc 2257710 0.10% 87878 4.05% 2019-03-31
Fidelity Management and Research Company 2263025 0.10% -54106 -2.34% 2019-03-31
FMR Inc 2307625 0.10% -51706 -2.19% 2019-03-31
Northern Trust Investments N A 2330848 0.10% 11457 0.49% 2019-03-31
Northern Trust Corp 2330848 0.10% 11457 0.49% 2019-03-31
Everett Harris & Co 3115538 0.13% 6535 0.21% 2019-03-31
BlackRock Advisors LLC 3265574 0.14% -171989 -5.00% 2019-07-31
Renaissance Technologies Corp 21344916 0.90% 600345 2.89% 2019-03-31
Advanced Series Trust 1898620 0.08% -86456 -4.36% 2019-01-31
Fidelity Management & Research Company 3676509 0.15% -2076 -0.06% 2018-11-30
Columbia Management Company 4469945 0.19% -80174 -1.76% 2018-06-30
Managed Account Advisors LLC 7386206 0.31% -150390 -2.00% 2018-06-30
State Street Corp 4919825 0.20% -71626 -1.43% 2018-06-30
Columbia Mangmt Investment Advisers, LLC 1973074 0.08% 109947 5.90% 2018-06-30
NGAM Advisors LP 1738358 0.07% -25054 -1.42% 2018-03-31
Eaton Vance Management 1522696 0.06% 7540 0.50% 2018-06-30
Saratoga Research & Investment Mgmt 1521596 0.06% -27083 -1.75% 2018-06-30
Royal Bank Of Canada 1191579 0.05% 39936 3.47% 2018-03-31
Manufacturers Life Insurance Co 2094258 0.09% -583 -0.03% 2018-03-31
Wells Fargo Advisors, LLC 1325118 0.05% -178978 -11.90% 2017-09-30
Morgan Stanley Smith Barney LLC 1222163 0.05% 146507 13.62% 2017-09-30
Dreyfus Corp 1267905 0.05% -61250 -4.61% 2017-09-30
Jennison Associates LLC 6412182 0.25% -10988619 -63.15% 2016-09-30
Capital Research & Mgmt Co - Division 3 2690700 0.10% 758600 39.26% 2016-09-30
Dividend Assets Capital, LLC 2531880 0.10% -81950 -3.14% 2016-09-30
Santa Barbara Asset Management 2266286 0.09% 392580 20.95% 2016-09-30
Capital Research and Management Company 2547100 0.10% 128000 5.29% 2016-12-31
Delaware Management Business Trust 2175872 0.08% -3221642 -59.69% 2016-09-30
Jackson Square Partners, LLC 6639477 0.26% -960904 -12.64% 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
DFA International Core Equity Portfolio 595283 0.03% -- -- 2019-06-30
Loomis Sayles Large Cap Growth Trust 1224476 0.05% 100696 8.96% 2019-03-31
CTIVP Loomis Sayles Growth Fund 1238816 0.05% -- -- 2019-06-30
Eaton Vance Tax Managed Growth 1.1 Fund 1287041 0.05% 3455 0.27% 2019-06-30
BlackRock Health Sciences Opps Port 1301900 0.05% -158300 -10.84% 2019-06-30
Bridge Builder Large Cap Growth Fund 1450138 0.06% -84906 -5.53% 2019-06-30
AST Loomis Sayles Large-Cap Growth Port 1452514 0.06% 17190 1.20% 2019-06-30
BlackRock Equity Dividend Fund 1926474 0.08% -13309 -0.69% 2019-06-30
Loomis Sayles Growth Fund 4676218 0.20% 83847 1.83% 2019-06-30
Loomis Sayles US Growth Equity Fund 1138405 0.05% 8232 0.73% 2019-06-30
JHancock Disciplined Value Fund 1110631 0.05% -- -- 2019-05-31
Amana Growth Fund 1002195 0.04% -- -- 2019-06-30
ClearBridge International Growth Fund 606690 0.03% 190770 45.87% 2019-06-30
Strategic Advisers 700368 0.03% 30278 4.52% 2019-06-30
MassMutual Select Blue Chip Growth Fund 759565 0.03% -6384 -0.83% 2019-06-30
Fidelity 800632 0.03% -272087 -25.36% 2019-04-30
American Funds Washington Mutual Fund 814900 0.03% -- -- 2019-06-30
JHancock US Global Leaders Growth Fund 838890 0.04% -- -- 2019-05-31
PGIM Jennison Health Sciences Fund 862119 0.04% -- -- 2019-06-30
USAA Growth Fund 970654 0.04% -5116 -0.52% 2019-06-30
Northwestern Mutual Ser FocApprec Port 539450 0.02% -11159 -2.03% 2019-03-31
Dreyfus Appreciation Fund 515205 0.02% -9300 -1.77% 2019-03-31
VA CollegeAmerica WA Mutl Inv Fd 814900 0.03% -- -- 2018-12-31
Eaton Vance Tax Managed Growth 1.0 Fund 1283586 0.05% -- -- 2018-12-31
AST Advanced Strategies Portfolio 432086 0.02% -29360 -6.36% 2018-12-31
Multi-Manager Growth Strategies Fund 443775 0.02% -3280 -0.73% 2018-12-31
Eaton Vance Tax Managed Growth 1.2 Fund 1283586 0.05% -- -- 2018-11-30
USAA International Fund 949158 0.04% 949158 -- 2018-02-28
Bridge Builder Large Cap Growth 1401552 0.06% 113795 8.84% 2018-06-30
AXA/Loomis Sayles Growth IA 363775 0.02% -2679 -0.73% 2018-07-31
VA CollegeAmerica WA Mutual 529B 451400 0.02% -- -- 2018-06-30
AST Advanced Strategies 494268 0.02% -23413 -4.52% 2018-07-31
Northwestern Mutual Ser Focused Apprec 578487 0.02% -11407 -1.93% 2018-06-30
Active Portfolios 541449 0.02% -- -- 2018-07-31
Dreyfus Appreciation Investor 588780 0.02% -22250 -3.64% 2018-07-31
DFA International Core Equity I 595283 0.02% -- -- 2018-07-31
Loomis Sayles Growth Y 5066842 0.21% -47777 -0.93% 2018-07-31
BlackRock Equity Dividend Inv B 3220219 0.13% -35164 -1.08% 2018-07-31
AST Loomis Sayles Large Cap Growth Port 1681417 0.07% -32230 -1.88% 2018-07-31
BlackRock Health Sciences Opps Inv A 1360000 0.06% -- -- 2018-07-31
Eaton Vance Tx-Mgd Growth 1.2 A 1283586 0.05% -- -- 2018-07-31
VP Loomis Sayles Growth 2 1247607 0.05% -15432 -1.22% 2018-07-31
USAA Growth 1093751 0.05% -75666 -6.47% 2018-07-31
JHancock US Global Leaders Growth A 1017083 0.04% -- -- 2018-07-31
Amana Growth Investor 1002195 0.04% -- -- 2018-08-31
MassMutual Select Blue Chip Growth R5 672802 0.03% 43826 6.97% 2018-06-30
State Farm Growth 357416 0.01% -- -- 2018-03-31
First Trust Value Line 452430 0.02% 1137 0.25% 2018-07-19
DFA Large Cap International I 540354 0.02% 479867 793.34% 2018-02-28
USAA International 949158 0.04% 949158 -- 2018-02-28
Fidelity Spartan 2384527 0.09% 29215 1.24% 2016-12-31
WCM Focused International Growth Instl 2059779 0.08% 86772 4.40% 2016-10-31
Vanguard US Growth Inv 1134911 0.04% -209340 -15.57% 2016-09-30
Goldman Sachs Rising Dividend Gr A 1150000 0.04% -920000 -44.44% 2016-12-31
Nuveen Santa Barbara Dividend Growth A 1136319 0.04% -- -- 2016-12-31
JNL/WCM Focused International Equity 723811 0.03% 15331 2.16% 2016-09-30
Fidelity® Series International Growth 5069281 0.20% 135000 2.70% 2015-08-31
Columbia Select Large Cap Growth Fund 3590520 0.10% 685080 23.60% 2015-08-31
VA CollegeAmerica Washington Mutual 2847100 0.10% -- -- 2015-09-30
Delaware U.S. Growth Fund 2286635 0.10% 25575 1.10% 2015-06-30
Goldman Sachs Rising Dividend Growth 2284100 0.10% -- -- 2015-09-30
AST Marsico Capital Growth 1717272 0.10% -49677 -2.80% 2015-08-31
Vanguard U.S. Growth Portfolio 1516955 0.10% -- -- 2015-06-30
VP Loomis Sayles Growth Fund 1455240 -- -14943 -1.00% 2015-08-31
Fidelity® Select Pharmaceuticals Port 1358100 -- -400 -- 2015-08-31
Active Portfolios® Multi-Manager Gr Fd 1246147 -- 174465 16.30% 2015-08-31
Nuveen Santa Barbara Dividend Growth Fd 1021795 -- -- -- 2015-09-30
Harbor Capital Appreciation Fund 7362676 0.30% -975599 -11.70% 2015-09-30

Sylvie Louise Gr�0�1�0�8goire Sylvie Louise Gr�0�1�0�8goire is a Canadian businessperson who founded EIP Pharma, Inc. and who has been at the head of 6 different companies. Currently, she holds the position of Chairman at Corvidia Therapeutics, Inc. and Executive Chairman of EIP Pharma, Inc. She is also on the board of 5 other companies. In her past career she occupied the position of Chairman for Metriopharm AG, Executive Vice President-Business Development at Biogen, Inc. and Executive Vice President-Technical Operations at Biogen MA, Inc. (a subsidiary of Biogen, Inc.), Executive Chairman at IDM Pharma, Inc., President, CEO & Executive Director at GlycoFi, Inc., President for Shire Human Genetic Therapies, Inc. and President-Human Genetic Therapies Division at Shire Plc. Dr. Gr�0�1�0�8goire received an undergraduate degree from Universit�0�1�0�8 Laval and a doctorate from State University of New York at Buffalo.
Helge Lund Helge Lund is a Norwegian businessperson who has been at the head of 5 different companies. Currently, he holds the position of Chairman of Novo Nordisk An and Chairman of BP Plc. He is also Chief Executive Officer-Oil Services at Schlumberger AG and on the board of 5 other companies. In his past career Mr. Lund held the position of President & Chief Executive Officer at Akastor ASA, President & Chief Executive Officer for Equinor ASA, Executive Director at BG Group Ltd. and Deputy Managing Director at Takeda AS. He received a graduate degree from Norwegian School of Economics & Business Administration and an MBA from INSEAD.
Elizabeth Anne Hewitt Ms. Elizabeth A. Hewitt is a Senior Independent Director at Melrose Industries Plc and an Independent Director at Novo Nordisk A/S. She is on the Board of Directors at Melrose Industries Plc, Novo Nordisk A/S, Novo Nordisk Ltd. and Silverwood Property Ltd. Ms. Hewitt was previously employed as an Independent Non-Executive Director by Savills Plc, an Independent Non-Executive Director by Melrose Holdings Plc, an Independent Non-Executive Director by Synergy Health Plc, a Group Director-Corporate Affairs by Smith & Nephew Plc, and a Trustee by Cancer Research UK. She received her undergraduate degree from the University College London.
Anne Marie Handrup Kverneland Anne Marie Handrup Kverneland is on the board of Novo Nordisk A, Novo Nordisk Fonden and Novo Nordisk Ltd. Ms. Kverneland received an undergraduate degree from Copenhagen University Hospital.
Jesper Brandgaard Jesper Brandgaard is a Danish businessperson who has been at the head of 13 different companies. Presently, Mr. Brandgaard holds the position of Chairman for Novo Nordisk Gsc Holding A, Chairman for Novo Nordisk Pharmaceuticals A, EVP-Biopharm & Legal Affairs at Novo Nordisk A, Chairman of Novo Nordisk Region Japan & Korea A, Chairman for Novo Nordisk Region China A, Chairman-Supervisory Board at Novo Nordisk Health Care AG and Chairman of Novo Nordisk Region North America Ii A (which are all subsidiaries of Novo Nordisk A) and Chairman of Novo Nordisk Invest 2 A. Jesper Brandgaard is also on the board of Chr. Hansen A, Chr. Hansen Holding A, Novo Nordisk Holding Ltd. and Novo Nordisk China Pharmaceuticals Co. Ltd. and Member of Novo Nordisk Haemophilia Foundation. Mr. Brandgaard previously was Chairman for NNIT A, Chairman for SimCorp A, Chairman of Novo Nordisk Invest 1 A, Chairman for Novo Nordisk Region International Operations A, Chairman of NNE Pharmaplan An and Chairman at Novo Nordisk Region Europe A. Jesper Brandgaard received a graduate degree and an MBA from Copenhagen Business School.
Mads Krogsgaard Thomsen Presently, Mads Krogsgaard Thomsen holds the position of Chairman at Steno Diabetes Center An and Chief Science Officer & Executive Vice President at Novo Nordisk A. Dr. Thomsen is also on the board of Symphogen An and Chairman for the University of Copenhagen. In his past career he occupied the position of President of The Danish Academy of Technical Sciences. Dr. Thomsen received a doctorate from the University of Copenhagen.
G�0�1�0�9ran Albert Ando Dr. G�0�1�0�9ran A. Ando, MD, is Vice Chairman, Head-Research & Development at Novo-Nordisk A, Chairman at The Southwest Michigan First Corp., Founder at American College of Rheumatology, and Chairman at SWMF Life Science Venture Fund LP. He is on the Board of Directors at Chroma Therapeutics Ltd., Molecular Partners AG, Archimedes Pharma UK Ltd., EUSA Pharma, Inc., CBio Ltd., Novo-Nordisk A, NicOx SA, S*BIO Pte Ltd., Novo A, Copenhagen Business School, Brisbane & Albea Pharmaceuticals AG, Eusa Pharma Europe Ltd., Albea Pharmaceuticals AG, and Bio*One Capital Pte Ltd. Dr. Ando was previously employed as Non-Executive Chairman by Inion Oy, Chief Executive Officer by Celltech Group Plc, EVP, President-Research & Development by Pharmacia Corp., President-Research & Development by Pfizer Australia Pty Ltd., Chairman by Novexel SA, Chairman by Pharmacia Biotech AB, Chairman-Supervisory Board by Trigen Holdings AG, EVP & Deputy Chief Executive Officer by Pharmacia AB, EVP-Worldwide Science & Technology by Pharmacia & Upjohn, Inc., and a Member-Scientific Council by H. Lundbeck A. He also served on the board at Glaxo Group Ltd., deCODE genetics, Inc., and Enzon Pharmaceuticals, Inc. He received his doctorate degree from the University of Linkoping.
Jeppe Fonager Christiansen Founder of Fondsm�0�1�0�7glerselskabet Maj Invest A, Jeppe Fonager Christiansen is a Danish businessperson who has been the head of 7 different companies and is Chairman at Emlika ApS, Chairman for Haldor Tops�0�1�0�0e A, Chief Executive Officer for Maj Invest Holding A, Chief Executive Officer at Fondsm�0�1�0�7glerselskabet Maj Invest An and Chief Executive Officer of Fondsm�0�1�0�7glerselskabet Maj Invest A (both are subsidiaries of Maj Invest Holding A) and Chairman for Haldor Tops�0�1�0�0e A. Jeppe Fonager Christiansen is also Member of SC Triton Industry SRL and on the board of 8 other companies. In his past career Mr. Christiansen held the position of Chief Executive Officer at Ld Pensions, Executive Vice President for L�0�1�0�0nmodtagernes Dyrtidsfond, Economist of Sparekassen SDS A, Fund Manager at Ld Pensions and Economist at SDS Holding A. Mr. Christiansen received a graduate degree from the University of Copenhagen.
Martin MacKay Martin MacKay is an American businessperson who founded Rallybio LLC and who has been the head of 6 different companies. Dr. MacKay holds the position of Chief Executive Officer & Director at Rallybio LLC and Chief Executive Officer of Calyx Group Plc. He is also on the board of Charles River Laboratories International, Inc. and Novo Nordisk A. He previously was Operations Director at Dun & Bradstreet Corp., Global Head-Research & Development at Alexion Pharmaceuticals, Inc., Senior Vice President-Worldwide Development at Pfizer Inc. and President for Pfizer Global Research & Development (a subsidiary of Pfizer Inc.), Vice President-International at VeriSign, Inc., Principal at PeopleSoft USA, Inc., President-Research & Development at AstraZeneca Plc, Principal at Beecham Pharmaceuticals (UK), Chief Executive Officer & Director at Neverfail, Inc., Chief Executive Officer at Vecta Software Corp. Ltd., Chief Executive Officer & Director at Neverfail Group Ltd., Head-Drug Preformulation & Delivery at BASF Performance Products Plc, Principal at Accenture LLC, Head-Molecular & Cell Biology at CRI Worldwide LLC, Director-Business Development of NorthgateArinso, Inc. and Head-Drug Preformulation & Delivery at Ciba-Geigy Pharmaceuticals. He received an undergraduate degree from Heriot-Watt University and a doctorate from The University of Edinburgh.
Brian F. Daniels Brian F. Daniels is Partner at 5AM Venture Management LLC. Dr. Daniels is also on the board of 8 other companies. Dr. Daniels previously occupied the position of Senior Vice President-Global Development at Bristol-Myers Squibb Co., Principal at Merck Research Laboratories and Principal at Genentech, Inc. Brian F. Daniels received a graduate degree and an undergraduate degree from Massachusetts Institute of Technology and a graduate degree from Washington University School of Medicine.
Peter Hugreffe Ankersen Peter Hugreffe Ankersen occupies the position of Vice President & Head-Investor Relations at Novo Nordisk A. In the past he held the position of Head of Research at ABG Sundal Collier ASA (Denmark) and Analyst at SEB Enskilda (Denmark). He received an MBA from Copenhagen Business School.
Stig Str�0�1�0�0b�0�1�0�7k Stig Str�0�1�0�0b�0�1�0�7k is on the board of Novo Nordisk An and Novo Nordisk Ltd.
S�0�1�0�0ren Thuesen Pedersen S�0�1�0�0ren Thuesen Pedersen is on the board of Novo Nordisk An and 5 other companies. Mr. Pedersen previously occupied the position of Chief Executive Officer for Jurag Separation ApS, Vice President-Marketing & Sales at Upfront Chromatography A, Marketing Manager at Novozymes An and Sales Manager at Superfos Pharma Pack A. He received an undergraduate degree from Technical University of Denmark.
Laurence Debroux Ms. Laurence Debroux is a Chief Financial Officer at Heineken NV, a Chief Financial Officer at Heineken Holding NV and an Independent Non-Executive Director at EXOR NV. She is on the Board of Directors at Novo Nordisk A/S, Bpifrance Participations SA, MediaKiosk SAS, M�0�1�0�8dia A�0�1�0�8roports de Paris SAS, JCDecaux Bollore Holding, �0�1‰cole des Hautes �0�1‰tudes Commerciales de Paris and EXOR NV. Ms. Debroux was previously employed as a Chief Financial & Administrative Officer by JCDecaux SA, an Independent Director by Natixis SA, and a Chairman by Sanofi-Aventis SA. She also served on the board at APG SGA SA. She received her undergraduate degree from �0�1‰cole des Hautes �0�1‰tudes Commerciales de Paris.
Kasim Kutay Kasim Kutay is Chief Executive Officer for Novo Principal Investments, Chief Executive Officer for Novo Holdings An and President & Chief Executive Officer for Novo Holding A. He is also on the board of Novo Nordisk A, Novozymes An and Novo Nordisk Ltd. and Managing Director at Moelis Asset Management LP. In his past career Mr. Kutay held the position of Managing Director at Sun Group Enterprises, Inc., Managing Director at Morgan Stanley & Co. LLC, Managing Director at Moelis & Co. (UK) LLP and Managing Director at Moelis & Co. LLC. Kasim Kutay received an undergraduate degree and a graduate degree from London School of Economics & Political Science.
Andreas Fibig Currently, Andreas Fibig occupies the position of Chairman & Chief Executive Officer of International Flavors & Fragrances, Inc. and Chairman at Max Planck Institute For Infection Biology. Mr. Fibig is also on the board of Novo Nordisk A, World Business Council for Sustainable Development, European Federation of Pharmaceutical Industries & Assns and Verband Forschender Arzneimittelhersteller e.V. and Member of German Academy of New York and Member of German American Chamber of Commerce, Inc. In his past career he occupied the position of Senior VP-US Pharmaceutical Operations Group at Pfizer Inc. and President-Market at Pharmacia GmbH (a subsidiary of Pfizer Inc.), Chairman & President of Bayer HealthCare Pharmaceuticals, Inc., Chairman of Bayer Pharma AG, Principal at Boehringer Ingelheim GmbH and Director-Sales & Marketing for Bayer Schering Pharma AG. Mr. Fibig received an undergraduate degree from Hochschule f�0�1�0�4r Wirtschaft und Recht Berlin.
Lars Fruergaard J�0�1�0�0rgensen Currently, Lars Fruergaard J�0�1�0�0rgensen occupies the position of President & Chief Executive Officer of Novo Nordisk An and President & Chief Executive Officer at Novo Nordisk Ltd. (a subsidiary of Novo Nordisk A) and Chairman at Harno Invest A. Mr. J�0�1�0�0rgensen is also on the board of Carlsberg A. In his past career Mr. J�0�1�0�0rgensen was Chairman at NNE Pharmaplan An and Vice President-Finance & Information Technology at Novo Nordisk SAS. Lars Fruergaard J�0�1�0�0rgensen received an MBA and a graduate degree from the University of Aarhus.
Alan C. Moses Alan C. Moses occupies the position of Senior Vice President & Chief Medical Officer at Novo Nordisk A. He is also on the board of Steno Diabetes Center A. He previously was Global Chief Medical Officer & Senior VP at Novo Nordisk, Inc., Fellow at American College of Physicians, Inc., Chief Medical Officer & Senior Vice President of Joslin Diabetes Center and Professor at Harvard University. Alan C. Moses received an undergraduate degree from Duke University and a doctorate from Washington University in St. Louis.
Lars Fruergaard J�0�1�0�0rgensen Currently, Lars Fruergaard J�0�1�0�0rgensen occupies the position of President & Chief Executive Officer of Novo Nordisk An and President & Chief Executive Officer at Novo Nordisk Ltd. (a subsidiary of Novo Nordisk A) and Chairman at Harno Invest A. Mr. J�0�1�0�0rgensen is also on the board of Carlsberg A. In his past career Mr. J�0�1�0�0rgensen was Chairman at NNE Pharmaplan An and Vice President-Finance & Information Technology at Novo Nordisk SAS. Lars Fruergaard J�0�1�0�0rgensen received an MBA and a graduate degree from the University of Aarhus.
Lars Fruergaard J�0�1�0�0rgensen Currently, Lars Fruergaard J�0�1�0�0rgensen occupies the position of President & Chief Executive Officer of Novo Nordisk An and President & Chief Executive Officer at Novo Nordisk Ltd. (a subsidiary of Novo Nordisk A) and Chairman at Harno Invest A. Mr. J�0�1�0�0rgensen is also on the board of Carlsberg A. In his past career Mr. J�0�1�0�0rgensen was Chairman at NNE Pharmaplan An and Vice President-Finance & Information Technology at Novo Nordisk SAS. Lars Fruergaard J�0�1�0�0rgensen received an MBA and a graduate degree from the University of Aarhus.
Lars Fruergaard J�0�1�0�0rgensen Currently, Lars Fruergaard J�0�1�0�0rgensen occupies the position of President & Chief Executive Officer of Novo Nordisk An and President & Chief Executive Officer at Novo Nordisk Ltd. (a subsidiary of Novo Nordisk A) and Chairman at Harno Invest A. Mr. J�0�1�0�0rgensen is also on the board of Carlsberg A. In his past career Mr. J�0�1�0�0rgensen was Chairman at NNE Pharmaplan An and Vice President-Finance & Information Technology at Novo Nordisk SAS. Lars Fruergaard J�0�1�0�0rgensen received an MBA and a graduate degree from the University of Aarhus.
Lars Fruergaard J�0�1�0�0rgensen Currently, Lars Fruergaard J�0�1�0�0rgensen occupies the position of President & Chief Executive Officer of Novo Nordisk An and President & Chief Executive Officer at Novo Nordisk Ltd. (a subsidiary of Novo Nordisk A) and Chairman at Harno Invest A. Mr. J�0�1�0�0rgensen is also on the board of Carlsberg A. In his past career Mr. J�0�1�0�0rgensen was Chairman at NNE Pharmaplan An and Vice President-Finance & Information Technology at Novo Nordisk SAS. Lars Fruergaard J�0�1�0�0rgensen received an MBA and a graduate degree from the University of Aarhus.
Jesper Giede B�0�1�0�0ving Mr. Jesper Giede B�0�1�0�0ving is Senior Vice President-CMC Supply at Novo Nordisk A/S.
Lars Green Lars Green holds the position of Executive VP, Head-Business Services & Compliance at Novo Nordisk An and Senior Vice President-Finance & Operations at Novo Nordisk, Inc. (a subsidiary of Novo Nordisk A). He is also on the board of Novozymes A. In his past career he occupied the position of Senior Vice President-Corporate Finance at Novo Nordisk A. He received a graduate degree from the University of Aarhus.
Jesper Giede B�0�1�0�0ving Mr. Jesper Giede B�0�1�0�0ving is Senior Vice President-CMC Supply at Novo Nordisk A/S.
Peter Jens Lindholm Kurtzhals Peter Jens Lindholm Kurtzhals is on the board of Danmarks Farmaceutiske Universitet, Medicon Valley Alliance FMBA, Steno Diabetes Center An and InnovationsFonden and Senior Vice President-Global Research at Novo Nordisk A. He previously was Senior Vice President-Diabetes Research Unit at Novo Nordisk A. He received a doctorate and a graduate degree from Danmarks Farmaceutiske Universitet.
Henrik Ehlers Wulff Presently, Henrik Ehlers Wulff is Chairman at Novo Nordisk Pharmatech A. He is also on the board of Ambu An and Executive Vice President-Product Supply at Novo Nordisk A. Mr. Wulff received a graduate degree from Technical University of Denmark.
Karsten Munk Knudsen Karsten Munk Knudsen is Chief Financial Officer & Executive Vice President of Novo Nordisk A. In his past career Mr. Knudsen held the position of Head-Finance at NNIT A, Principal at A.P. M�0�1�0�0ller-M�0�1�0�7rsk A, Financial Analyst at Nykredit Bank An and Corporate Vice President-Finance & IT at Novo Nordisk, Inc. He received a graduate degree from the University of Aarhus.
Camilla Sylvest Camilla Sylvest is on the board of Danish Crown An and Senior Vice President & General Manager-Germany at Novo Nordisk Pharma GmbH and EVP-Commercial Strategy & Corporate Affairs at Novo Nordisk A. She received an MBA from Scandinavian International Management Institute and an undergraduate degree from the University of Southern Denmark.
J�0�1�0�0rn Roland M�0�1�0�4ller Mr. J�0�1�0�0rn Roland M�0�1�0�4ller is Vice President & Head-Biopharm Sourcing at Novo Nordisk A/S.
J�0�1�0�0rn Roland M�0�1�0�4ller Mr. J�0�1�0�0rn Roland M�0�1�0�4ller is Vice President & Head-Biopharm Sourcing at Novo Nordisk A/S.
Maziar Mike Doustdar Currently, Maziar Mike Doustdar holds the position of Executive Vice President-International Operations at Novo Nordisk An and Managing Director at Novo Nordisk Health Care AG and EVP & Head-International Operations at Novo Nordisk Ltd. (both are subsidiaries of Novo Nordisk A). Mr. Doustdar received an undergraduate degree from Webster University.
S�0�1�0�0ren Thuesen Pedersen Ms. Betina Woythal is VP-Corporate Occupational Health & Safety at Novo Nordisk A/S.
Jeppe Fonager Christiansen Founder of Fondsm�0�1�0�7glerselskabet Maj Invest A, Jeppe Fonager Christiansen is a Danish businessperson who has been the head of 7 different companies and is Chairman at Emlika ApS, Chairman for Haldor Tops�0�1�0�0e A, Chief Executive Officer for Maj Invest Holding A, Chief Executive Officer at Fondsm�0�1�0�7glerselskabet Maj Invest An and Chief Executive Officer of Fondsm�0�1�0�7glerselskabet Maj Invest A (both are subsidiaries of Maj Invest Holding A) and Chairman for Haldor Tops�0�1�0�0e A. Jeppe Fonager Christiansen is also Member of SC Triton Industry SRL and on the board of 8 other companies. In his past career Mr. Christiansen held the position of Chief Executive Officer at Ld Pensions, Executive Vice President for L�0�1�0�0nmodtagernes Dyrtidsfond, Economist of Sparekassen SDS A, Fund Manager at Ld Pensions and Economist at SDS Holding A. Mr. Christiansen received a graduate degree from the University of Copenhagen.
Jeppe Fonager Christiansen Founder of Fondsm�0�1�0�7glerselskabet Maj Invest A, Jeppe Fonager Christiansen is a Danish businessperson who has been the head of 7 different companies and is Chairman at Emlika ApS, Chairman for Haldor Tops�0�1�0�0e A, Chief Executive Officer for Maj Invest Holding A, Chief Executive Officer at Fondsm�0�1�0�7glerselskabet Maj Invest An and Chief Executive Officer of Fondsm�0�1�0�7glerselskabet Maj Invest A (both are subsidiaries of Maj Invest Holding A) and Chairman for Haldor Tops�0�1�0�0e A. Jeppe Fonager Christiansen is also Member of SC Triton Industry SRL and on the board of 8 other companies. In his past career Mr. Christiansen held the position of Chief Executive Officer at Ld Pensions, Executive Vice President for L�0�1�0�0nmodtagernes Dyrtidsfond, Economist of Sparekassen SDS A, Fund Manager at Ld Pensions and Economist at SDS Holding A. Mr. Christiansen received a graduate degree from the University of Copenhagen.
Doug Langa Doug Langa is EVP & Head-North America Operations at Novo Nordisk A. In the past Mr. Langa was Director-Payer Marketing at GlaxoSmithKline Pharma A. Mr. Langa received an undergraduate degree from Widener University and an MBA from Fordham University.
Krisja Vermeylen Krisja Vermeylen is Senior Vice President-People & Organisation at Novo Nordisk A. She is also on the board of MorphoSys AG. In her past career Ms. Vermeylen occupied the position of Manager-Marketing & Sales at Novo Nordisk An and Vice President of Novo Nordisk SAS (a subsidiary of Novo Nordisk A). She received a graduate degree and a doctorate from the University of Antwerp.
Camilla Sylvest Camilla Sylvest is on the board of Danish Crown An and Senior Vice President & General Manager-Germany at Novo Nordisk Pharma GmbH and EVP-Commercial Strategy & Corporate Affairs at Novo Nordisk A. She received an MBA from Scandinavian International Management Institute and an undergraduate degree from the University of Southern Denmark.
Mette B�0�1�0�0jer Jensen Camilla Sylvest is on the board of Danish Crown An and Senior Vice President & General Manager-Germany at Novo Nordisk Pharma GmbH and EVP-Commercial Strategy & Corporate Affairs at Novo Nordisk A. She received an MBA from Scandinavian International Management Institute and an undergraduate degree from the University of Southern Denmark.
Mette B�0�1�0�0jer Jensen Mette B�0�1�0�0jer Jensen is on the board of Novo Nordisk A. Ms. Jensen received a graduate degree from the University of Aalborg.
Thomas Rantzau Thomas Rantzau is on the board of Novo Nordisk A. He received an undergraduate degree from Technical University of Denmark.
Marcus Schindler Marcus Schindler is on the board of Innate Pharma SA and Director, SVP-External Innovation & Strategy at Novo Nordisk A. Mr. Schindler received a doctorate from the University of Cambridge.
Stephen Gough Stephen Gough is Global Chief Medical Officer at Novo Nordisk A.
Robin Evers Robin Evers is SVP-Medical Affairs, Regulatory & Safety at Novo Nordisk A.
Martin Holst Lange Martin Holst Lange is on the board of Beta Bionics, Inc. and Senior Vice President-Global Development at Novo Nordisk A.
Robin Evers Robin Evers is SVP-Medical Affairs, Regulatory & Safety at Novo Nordisk A.
Ludovic Helfgott Ludovic Helfgott is Executive Vice President for Novo Nordisk A.

量化对比

全部评论 3

  • 【胰岛素国采全面降价将至:武汉试点“灵魂砍价”最高降43%】根据国家医保局近日消息,生物制品(含胰岛素)和中成药也将启动带量采购,目前已进入听取专家意见建议阶段。其中胰岛素被着重提及。今年1月,武汉医保局率先试水胰岛素带量采购,与诺和诺德、礼来、通化东宝、甘李药业等九家企业展开降价谈判,最终促成部分中标胰岛素类药品单价最高降43%。据生物药集采专家透露,针对胰岛素等生物制品和中成药的带量采购,预计最快将于2021年初完成初稿。(华夏时报)

  • 【胰岛素国采全面降价将至:武汉试点“灵魂砍价”最高降43%】根据国家医保局近日消息,生物制品(含胰岛素)和中成药也将启动带量采购,目前已进入听取专家意见建议阶段。其中胰岛素被着重提及。今年1月,武汉医保局率先试水胰岛素带量采购,与诺和诺德、礼来、通化东宝、甘李药业等九家企业展开降价谈判,最终促成部分中标胰岛素类药品单价最高降43%。据生物药集采专家透露,针对胰岛素等生物制品和中成药的带量采购,预计最快将于2021年初完成初稿。(华夏时报)

  • 丹麦生物制药公司诺和诺德第一季度息税前利润16.3亿丹麦克朗,预计14.59亿丹麦克朗。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐